Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 250-284-7 | CAS number: 30674-80-7
Skin irritation (OECD 404): irritatingEye irritation (non-guideline study): corrosiveRespiratory irriation (similar to OECD 403): irritating
In the available key study (Bozo Research Center, Inc., 2005) the test item was investigated for skin irritating/corrosive properties according to the OECD test guideline 404, and in compliance with GLP. Each of three Japanese White rabbits was semiocclusively administered the undiluted test material for 3 min, 1 h, and 4 h. Untreated skin was covered in the same manner and served as control site. After 4 h of exposure, the mean erythema score for all animals over 24, 48, and 72 h was 3.1, with one animal showing the max. score of 4. The effect was fully reversible in two animals within 7 and 9 days, respectively, whereas in the third animal the erythema score of 4 persisted until study termination. The mean oedema score after 4 h of treatment was 2.2, with a max. score of 4 in one animal after 24 h. Oedema were fully reversible within 7, 8, and 13 days, respectively. After 1 h of exposure, the mean erythema and oedema scores of all three animals over 24, 48, and 72 h were 2.7 and 2.0, respectively, with erythema scores never exceeding a score of 3 and oedema never exceeding a score of 2 in any of the animals. On day 10 following exposure none of the animals showed any skin reactions on this test site. Exposure to the test item for 3 min revealed mean erythema and oedema scores of 1.4 and 0.4, respectively, whereas erythema never exceeded a score of 2 and oedema never exceeded a score of 1. On day 8 of the observation period neither erythema nor oedema were observed in any of the animals at this test site. As other skin reactions scaling was observed in 2/3, 3/3, and 2/3 animals after 4 h, 1 h, and 3 min of exposure, respectively. Eschar formation was observed only in 1/3 animals after 4 h of treatment, but in none animal after 1 h and 3 min of exposure. There were no findings in any of the animals at any test site suggesting corrosiveness of the test item. There were no abnormalities in the general condition and the body weight development of any animal during the observation period. Based on the outcome of the study the test item meets the criteria to be classified for skin irritancy (Xi, R38) according to 67/584/EEC and (Cat 2, H315) according to EC/1272/2008.
In the available key study (DuPont, 1976) the test item was investigated for eye irritating properties. Two albino rabbits received 0.1 mL of the undiluted test material into the conjunctival sac of one eye, whereas the other eye remained untreated and served as control. The eye of one animal was washed for 1 minute with tap water 20 seconds after test material instillation, whereas the treated eye of the second animal remained unwashed. The test item produced severe corneal opacity, mild to moderate iritis, and severe conjunctival irritation in an unwashed rabbit eye. At 21 days the eye was left with a corneal ulcer, almost total corneal pannus, and mild conjunctival irritation; whereas the iris was not visible. The eye treated with the test item and promptly washed had moderate to severe corneal opacity, moderate irritis, and severe conjunctival irritation. At 21 days there remained a corneal ulcer, > 3/4 corneal pannus, and mild conjunctival irritation; the iris was normal. In conclusion, the test item is a severe eye irritant, which produces irreversible ocular effects. Hence, the test substance meets the criteria to be classified for risk of serious damage to eyes (Xi, R41) according to 67/584/EEC and irreversible effects on the eye (Cat 1, H318) according to EC/1272/2008.
No study is available investigating the respiratory properties of the submission substance. However, data obtained from an acute inhalation toxicity study (Dow Chemical U.S.A., 1978) revealed strong irritating effects on the respiratory tract after inhalation exposure. 10 Fischer 344 rats per sex per dose were exposed to vaporised test material in a whole-body inhalation system for 1 and 6 h, respectively. The doses applied into the inhalation chamber were 40, 20, and 10 ppm (equal to 0.2533, 0.1267, and 0.0633 mg/L) for 1 h and 7, 4, and 2 ppm (equal to 0.0443, 0.0253, and 0.0127 mg/L) for the 6 h exposure duration. The LC50 determined was 4.4 ppm (equal to 0.0281 mg/L). In the 6 h exposure experiment rats exposed to the test material showed progressively increased signs of eye and nasal irritation and respiratory difficulties during treatment. Just after exposure there were signs of eye irritation, and dried dark red-brown exudate on the noses; respiratory difficulties appeared to have diminished, only slight rales being observable in a few rats. 16 h later there was evidence of severe respiratory distress in all animals exposed. Clinical signs in the animals treated for 1 h developed much more quickly than in the 6 hour exposure experiment. During exposures, all rats showed signs of eye and nasal irritation and respiratory difficulties. After exposure and a 30 min venting period, both male and female rats, showed diminished signs of respiratory difficulties, but did show laboured breathing, stains on their noses, and appeared lethargic.
The incidence of the effects observed showed a clear dose-relationship. Gross pathology revealed generally effects on the respiratory tract, as well as irritating effects to the eyes.
Data obtained from the repeated dose toxicity study via the inhalation route (The Dow Chemical Company, 1980) also indicate irritating effects to the respiratory system. 20 Fischer 344 rats per sex per dose were treated with vapour of the test item in a whole-body inhalation system for 6 h/day and 5 days/week for 13 consecutive weeks at doses of 25, 80, and 250 ppb (equivalent to 1.583, 0.507, and 0.158 mg/m³), whereas control animals were treated with the vehicle only (air). At the end of the exposure period 10 animals per sex per dose were sacrificed. In order to assess the reversibility of treatment-related effects and to identify potential latent effects of exposure, the remaining 10 animals per sex per dose were maintained for further 30 and 90 days of observation, respectively. Although no clinical signs were observed, histopathological examination revealed hyperplasia of the respiratory epithelium lining the nasal turbinates was observed in 4/10 males and 5/10 females of the high dose group and 3/10 males of the mid dose group. However, the effect was reversible, since it was not observed in any of the recovery groups.
In conclusion, the registered substance exhibits transient respiratory irritating properties in a dose-dependent manner. According to the Guidance on the Application of Regulation (EC) No 1272/2008, Section 18.104.22.168, the registered substance would meet the criteria for classification with STOT SE Cat 3 (H335, May cause respiratory irritation), since “Category 3 effects should be confined to changes, whether functional or morphological, occurring in the upper respiratory tract (…). Localised irritation with associated adaptive responses (…) may occur and are consistent with Category 3 responses.” However, due to the fact that rats are obligatory nasal breathing, the effects observed are considered to be less severe in humans. In addition, the substance meets the criteria to be classified as very toxic after inhalation (T+, R26 according to 67/584/EEC and Cat 1, H330 according to EC/1272/2008) and safety precautions conducted for acute inhalation toxicity will also cover the risk of respiratory irritation. This is in accordance with Annex I: 22.214.171.124.1 of the Guidance on the Application of Regulation (EC) No 1272/2008: “(e) this special classification would occur only when more severe organ effects including in the respiratory system are not observed”. In the acute inhalation toxicity study strong irritating effects on the respiratory tract were observed, which caused mortality and lead to the classification of acute toxicity via inhalation. In accordance with Section 126.96.36.199: “… a double classification for the same effect has to be avoided”, classification for respiratory irritation is considered superfluous and therefore not warranted.
The available data are reliable and suitable for classification. Based on this data, the registered substance meets the criteria to be classified for risk of serious damage to eyes (Xi, R41) and skin irritancy (Xi, R38) according to 67/584/EEC and irreversible effects on the eye (Cat 1, H318) and skin irritancy (Cat 2, H315) according to EC/1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Close Do not show this message again